ALX Oncology appoints Scott Garland as Chairman, Michael Listgarten as General Counsel; co-founder resigns

ALX ONCOLOGY HOLDINGS INC

Co-founder Corey Goodman resigned as Chairman and board member effective June 29, 2026, for personal reasons.
Scott Garland, independent director since Nov 2022, appointed Chairman of the Board.
Michael Listgarten appointed General Counsel, effective immediately.
Company advancing evorpacept into late-stage development and progressing ALX2004.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.